• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Teleflex touts large real-world UroLift study

Teleflex touts large real-world UroLift study

July 10, 2019 By Danielle Kirsh

TeleflexTeleflex (NYSE:TFX) yesterday touted results from a real-world study of its UroLift system for treating prostate disease.

The UroLift implant is designed to treat lower urinary tract symptoms from benign prostatic hyperplasia. Wayne, Pa.-based Teleflex paid $1 billion to acquire NeoTract, which developed UroLift, in October 2017.

The 1,413-patient retrospective study was designed to evaluate UroLift’s safety and effectiveness in a real-world setting, measuring International Prostate Symptom and Quality of Life scores through two years. Results were published in the Journal of Endourology.

Symptoms improved “significantly” at all follow-up points, with mostly mild to moderate peri-operative adverse events that resolved within four weeks, the company said. There were 165 patients in retention at baseline, with 83% catheter-free at one month and 87% catheter-free at two years, with similar IPSS scores to non-retention patients. Of 73 patients who were previously treated for prostate cancer, mean IPSS improved at all follow-ups with no significant differences in adverse events. And IPSS improvement was similar across prostate volumes, Teleflex said.

“Not only are the real-world results from this large, multi-center study consistent with the LIFT study, this study also provides data in the populations of patients who were not studied in the LIFT study but are seen in a real-world clinic setting,” lead investigator and co-author Dr. Gregg Eure said in a press release. “These findings should give urologists and patients the confidence to adopt the UroLift System within the broader BPH population.”

“With over 100,000 men treated worldwide, the UroLift System has become an accepted standard of care treatment for BPH that provides patients rapid symptom relief and recovery,” added interventional urology president Dave Amerson. “We are pleased that these highly positive results continue to demonstrate that outcomes found in a real-world setting are consistent with those in the pivotal LIFT study, and also highlight the effectiveness and versatility of the UroLift System treatment for BPH in diverse patient populations.”

Filed Under: Clinical Trials, Surgical, Urology Tagged With: Teleflex

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy